Trials / Completed
CompletedNCT02598440
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 341 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alendronate | Participants wil receive once-weekly oral alendronate (70 mg tablet) |
| DRUG | Ibandronate | Participants wil receive once-monthly oral ibandronate (150 mg tablet) |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-05-01
- Completion
- 2005-05-01
- First posted
- 2015-11-05
- Last updated
- 2016-11-02
Locations
54 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02598440. Inclusion in this directory is not an endorsement.